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Recombinant forms of the dengue 2 virus NS3 prote-
ase linked to a 40-residue co-factor, corresponding to
part of NS2B, have been expressed in Escherichia coli
and shown to be active against para-nitroanilide sub-
strates comprising the P6-P1 residues of four substrate
cleavage sequences. The enzyme is inactive alone or
after the addition of a putative 13-residue co-factor pep-
tide but is active when fused to the 40-residue co-factor,
by either a cleavable or a noncleavable glycine linker.
The NS4B/NS5 cleavage site was processed most readily,
with optimal processing conditions being pH 9, I  10
mM, 1 mM CHAPS, 20% glycerol. A longer 10-residue pep-
tide corresponding to the NS2B/NS3 cleavage site (P6-
P4) was a poorer substrate than the hexapeptide (P6-
P1) para-nitroanilide substrate under these conditions,
suggesting that the prime side substrate residues did
not contribute significantly to protease binding. We also
report the first inhibitors of a co-factor-complexed, cat-
alytically active flavivirus NS3 protease. Aprotinin was
the only standard serine protease inhibitor to be active,
whereas a number of peptide substrate analogues were
found to be competitive inhibitors at micromolar
concentrations.
Dengue viruses belong to the flaviviridae family and are
transmitted via mosquitoes to millions of people each year in
tropical and subtropical regions of the world. They consist of a
group of four serologically related viruses referred to as dengue
virus types 1–4, with infection resulting in a range of clinical
diseases such as dengue fever, dengue hemorrhagic fever, and
dengue shock syndrome (1). There is currently no approved
vaccine or effective antiviral therapy for these diseases. Like
other flaviviruses, the dengue viruses are enveloped with a
single, positive sense 11-kilobase RNA genome encoding one
long open reading frame. Gene expression involves both co- and
post-translational proteolytic processing of a large polyprotein
precursor into three structural proteins (C, prM, and E) and
seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A,
NS4B, and NS5) (Fig. 1A) (2). In addition to host proteases, a
single virus-encoded protease comprising the amino-terminal
180 amino acids of NS3 (NS3pro) is responsible for cleavage
both in cis and in trans to generate viral proteins that are
essential for viral replication and maturation of infectious den-
gue virions (3). NS3 is at least a trifunctional protein because
the carboxyl-terminal region encodes both nucleoside triphos-
phatase and helicase activities (4, 5).
The dengue virus NS3 protease shares with other flavivirus
NS3 proteases a trypsin-like character with a classic serine
protease catalytic triad (His51, Asp75, and Ser135) (6–8). Al-
though unlike trypsin it has a marked preference for dibasic
residues (e.g. Arg and Lys at P1 and P2) and requires the
co-factor activity supplied by the nonstructural protein NS2B
for efficient catalysis of the proteolytic cleavage of the dengue
virus polyprotein (3). The NS2B-NS3 conjugate has been shown
to cleave the precursor polyprotein at the NS2A/NS2B, NS2B/
NS3, NS3/NS4A, and NS4B/NS5 junctions as well as at inter-
nal sites within C, NS2A, NS3, and NS4A (9–11), whereas the
host cell proteases, signalase and furin, act on the remaining
cleavage sites (Fig. 1A) (12–15). Deletion studies employing
vaccinia recombinants have further shown that a central 40-
amino acid conserved hydrophilic domain within NS2B is suf-
ficient for co-factor activity (16). The flanking hydrophobic res-
idues of NS2B are likely to function by promoting association
between the protease complex and infected cell membranes
(17). The essential nature of the central hydrophilic domain for
proteolytic activity has been recently confirmed in vitro with
Escherichia coli expressed and purified recombinant NS3pro
complexed with this NS2B co-factor domain (18).
A therapeutic strategy based on inhibiting proteases (19–21)
has precedent in the success of HIV-11 protease inhibitors (19,
22, 23), which prevent HIV replication by blocking the viral
protease responsible for producing structural and functional
HIV proteins in host cells. To mount a similar antiviral pro-
gram for the dengue viruses, we describe in this paper the
expression and purification of two recombinant forms of NS3
protease and the preliminary characterization of the enzymol-
ogy, including limitations imposed by assay conditions, sub-
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strates, and co-factors. We also describe the activity of the first
substrate-based peptide inhibitors.
EXPERIMENTAL PROCEDURES
General Methods
Protected amino acids and resins were obtained from Novabiochem.
TFA, piperidine, DIPEA, and DMF (peptide synthesis grade) were
purchased from Auspep. All other materials were reagent grade unless
otherwise stated. Crude peptides were purified by reversed-phase
HPLC separations performed on a Waters Delta-Pak reversed-phase
C18 preparative column, using a gradient mixture of solvent A (0.1%
TFA with water) and solvent B (0.1% TFA, 10% water, and 90% aceto-
nitrile. Analytical HPLC was performed on a Waters system equipped
with a 717 plus autosampler, 660 controller, and a 996 photodiode array
detector using a reversed-phase C18 (Vydac 201HS5415) column or a
reversed-phase protein and peptide column (Vydac 218TP5415). Puri-
fied peptides were characterized by analytical HPLC (linear gradient
0–100% solvent B over 30 min) and mass spectrometry. The molecular
mass of the peptides was determined by electrospray mass spectrome-
try recorded on a triple quadrupole (PE SCIEX API III) and electros-
pray TOF (Applied Biosystems Mariner) mass spectrometers. 1H NMR
spectra were recorded on a Varian 300MHz or a Bruker 500MHz NMR
spectrometer at 303 K. Proton assignments were determined by two-
dimensional NMR experiments (double-quantum filtered correlation
spectroscopy, total correlation spectroscopy, and nuclear Overhauser
enhancement spectroscopy).
Plasmid Construction
Generation of NS2B.NS3pro PCR product for cloning. C6/36 cells
were infected with dengue 2 virus strain NGC at a multiplicity of
infection of 1.0 and incubated at 32 °C for 3 days. Infected cell RNA was
then extracted with RNazol B (Tel-Test Inc) according to the manufac-
turer’s instructions. cDNA was generated using the NS3proRXhoI re-
verse primer (5-TATACTCGAGCTATCGAAAAATGTCATCTT-3; re-
striction sites are underlined), which was then used as template in a
PCR reaction employing this primer and NS2BFNcoI (5-CAAACCAT-
GGCAAGCTGGCCGCTAAATGA-3). The resulting PCR product com-
prised the full NS2B sequence and the first 184 amino acids of NS3
(NS3pro) flanked by NcoI-XhoI sites for cloning into pTM1.
pTM1 Constructs
Four vectors were generated for eukaryotic in vitro translation anal-
yses: pTM.NS2B.NS3pro (full-length NS2B.NS3pro), pTM.NS3pro
(NS3pro alone), pTM.CF40.NS3pro (NS3pro fused to the 40 amino acid
co-factor domain of NS2B), and pTM.CF40.NS3pro (containing a mu-
tation in one of the amino acids comprising the NS3pro catalytic triad
Ser135 to Ala135) (Fig. 1B). The NS2B.NS3pro PCR product described
above was digested with NcoI and XhoI and cloned into the pTM1 vector
to generate pTM.NS2B.NS3pro. The primers NS3proFNcoI (5-CAAAC-
CATGGCTGGAGTATTGTGGGATGT-3) and NS3proRXhoI were used
in a PCR reaction with pTM.NS2B.NS3pro as template. The PCR
products were digested with NcoI and XhoI and cloned into the pTM1
vector to generate pTM.NS3pro. pTM.CF40.NS3pro was generated by
amplification of the ligation products of separate PCR reactions. The
two PCR products were amplified off the pTM.NS2B.NS3pro template
with the primer pairs, CF40FNcoI (5-AGGTACCATGGCCGATTTGG-
AACTG-3)/CF40RKpnI (5-GGGGTACCACAGTGTTTGTTCTTCCTC-
3) and NS3proFKpnI (5-GGGGTACCTGTGGGAAGTGAAGAAACAA-
CGGGCTGGAGTATTGT-3)/NS3proRXhoI. Both PCR products were
digested with KpnI, gel-purified, and then ligated. The products of the
ligation were then amplified with the outside primers CF40FNcoI and
NS3proRXhoI. The resulting PCR product, comprising the 40-amino
acid co-factor domain of NS2B fused to the 10 amino acids immediately
upstream of the NS2B-NS3 cleavage site and the first 184 amino acids
of NS3pro, was digested with NcoI and XhoI and cloned into the pTM1
vector. pTM.CF40.NS3pro was generated by PCR mutagenesis using
pTM.CF40.NS3pro as template and the complementary mutation prim-
ers NS3proFS135A (5-TCTCCTGGAACCGCAGGATCTCCAATC-3)
and NS3proRS135A (5-GATTGGAGATCCTGCGGTTCCAGGAGA-3)
in separate PCR reactions with NS3proRXhoI and CF40FncoI, respec-
tively. The nucleotide change leading to the S135A mutation is bold
type.
pQE9 Constructs
Three vectors were generated for the expression in E. coli of amino-
terminal His-tagged recombinant dengue viral NS3 protease:
pQE9.NS3pro, pQE9.CF40.NS3pro, and pQE9.CF40.gly.NS3pro (CF40
fused to NS3pro via a Gly4SerGly4 linker). pTM.CF40.NS3pro was used
as template for the generation of PCR products with the primer pairs
NS3proFBamHI (5-ATTAGGATCCCTGGAGTATTGTGGGATGT-
3)/NS3proRHindIII (5-GCTAAAGCTTCTATCGAAAAATGTCATCTT-
3) and CF40FBamHI (5-ATTAGGATCCGCCGATTTAGAACTG-
3)/NS3proRHindIII. PCR products were digested with BamHI and
HindIII and cloned into pQE9 to generate pQE9.NS3pro and pQE9.
CF40.NS3pro, respectively. pQE9.CF40.gly.NS3pro was generated by
overlap PCR using pQE9.CF40.NS3pro as template and the primer
pairs CF40FBamHI/CF40glyR (5-CCCGCCTCCACCACTACCTCCGC-
CCCCCAGTGTTTGTTCTTCCTC-3) and NS3proglyF (5-GGGGGCG-
GAGGTAGTGGTGGAGGCGGGGCTGGAGTATTGTGGGATG-3)/
FIG. 1. Flavivirus polyprotein processing and dengue 2 virus NS3 expression constructs. A shows sites on the flavivirus polyprotein
cleaved by host-encoded proteases (black arrows below) and the virus-encoded protease complex NS2B.NS3 (open arrows above). The NS2B
co-factor and the proteolytic domain of NS3 (NS3pro) are shaded. B, overview of the expression constructs used in this study. The shading in A
corresponds to the first construct and is designated NS2B.NS3pro. Highlighted on this construct in B are key features of the protease complex,
including the cleavage site (open arrow), the catalytic triad of NS3pro (asterisks), conserved hydrophobic domains of the NS2B co-factor (solid
boxes), and the minimum 40-residue co-factor region required for catalytic activity of NS3pro (solid bar). The remaining four constructs comprise
NS3pro alone (NS3pro), the central 40-amino acid NS2B co-factor domain fused to the 10 amino acids upstream of the NS2B/NS3 cleavage site,
the first 184 amino acids of NS3 (CF40.NS3pro), a construct containing a Ser to Ala catalytic triad mutation (CF40.NS3pro), and a construct
comprising the 40-amino acid co-factor domain tethered to NS3pro via a flexible linker (CF40.gly.NS3pro).
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NS3proRHindIII to amplify first round PCR products. These were
mixed in limiting concentration and then amplified with the outside
primers CF40FBamHI and NS3proRHindIII. The resulting PCR prod-
uct, comprising the 40-amino acid NS2B co-factor domain fused to
NS3pro via a flexible Gly4SerGly4 linker, was digested with BamHI and
HindIII and cloned into pQE9. All constructs were confirmed by auto-
mated sequence analysis.
Expression and Purification of NS3pro, CF40.NS3pro, and
CF40.gly.NS3pro
The pQE9 vector was used for high level, inducible expression of
amino-terminal hexahistidine-tagged recombinant proteins. Cultures
of E. coli strain SG13009, transformed with the corresponding expres-
sion plasmids, were grown in 2 liters of LB medium containing 100
g/ml ampicillin and 25 g/ml kanamycin at 37 °C until the A600 nm
reached 0.6. The cells were induced for expression by the addition of
isopropyl--D-thiogalactopyranose to a final concentration of 1 mM and
incubated for an additional 3 h at 30 °C. The cells were then harvested
by centrifugation, and the pellets were stored at 80 °C until used. For
protein purification, the cells were thawed and resuspended in 1 ml of
lysis buffer (50 mM HEPES, pH 7.5, 300 mM NaCl, 5% glycerol)/10 ml of
original culture. The resuspended cells were lysed by French press or
subjected to probe sonication (five 30-s pulses) on ice and then centri-
fuged at 27,000  g for 30 min at 4 °C. The supernatant was stored at
4 °C or purified immediately by passage through a 2-ml column of
Ni2-nitrilotriacetic acid-agarose (Qiagen) pre-equilibrated with 50 mM
HEPES, pH 7.5, containing 300 mM NaCl. The column was extensively
washed with buffer containing 20 mM imidazole, and protein was then
eluted from the column in buffer containing 100 mM imidazole. Elution
fractions were analyzed by 15% SDS-PAGE. Samples of pre- and post-
induced cells as well as soluble and insoluble fractions following lysis
were collected and also analyzed by 15% SDS-PAGE.
In Vitro Transcription and Translation
An in vitro rabbit reticulocyte-coupled transcription/translation sys-
tem (TnT, Promega) was used to express recombinant protein from the
pTM1 vector constructs. The reactions were performed according to the
manufacturer’s instructions. Briefly, [35S]methionine-labeled protein
was expressed by incubation of 0.5 g of vector DNA with reticulocyte
lysate, amino acid (minus methionine) mixture, RNasin, T7 RNA po-
lymerase, and 10.0 Ci of [35S]methionine in a final volume of 25 l at
30 °C for 90 min. Reactions requiring membranes included 3 l of
canine pancreatic microsomal membranes. The reactions were termi-
nated by the addition of SDS containing gel buffer, and the products
were examined by 15% SDS-PAGE and autoradiography.
Peptide Substrates
para-Nitroanilide (pNA) substrates were synthesized by solid phase
synthesis (24) using Fmoc protecting groups for the following amino
acids: Arg (pmc), Glu (OtBu), Gln (trt), Lys (boc), Ser (tBu), and Thr
(tBu). The Fmoc protecting group was removed by shaking the resin
with two 1-min treatments with 50% piperidine in dimethylformamide.
All amino acids (4 meq) were activated by HBTU (4 meq) and DIPEA (5
meq) in DMF. Couplings were monitored by the quantitative ninhydrin
test. All peptides were acetylated with acetic anhydride (20 meq) and
DIPEA (10 meq) after the final Fmoc deprotection. Peptide p-aminoani-
lides were assembled on modified chloride trityl resin (substitution
value  0.96 mmol/g) and subsequently cleaved from the solid support
with 95% TFA, 2.5% triisopropylsilane, and 2.5% water (15 ml/g resin)
for 1 h at room temperature. The respective p-aminoanilides were
oxidized with oxone (6 meq) in water. Crude peptides were purified by
reverse-phase HPLC and lyophilized overnight to give pure p-nitroani-
lides in good yield (50–80%). The 10-residue peptide substrate was
assembled on N-Boc-leucine 4-hydroxymethylphenylacetic acid resin
(substitution value  0.79 mmol/g) (Novabiochem). Protecting groups
for individual amino acids were: Arg (Tos), Glu (CHx), and Lys (2-Cl-Z).
Removal of the Boc protecting group was effected by shaking the resin
twice with 1-min treatments with TFA. All amino acids (4 meq) were
activated by HBTU (4 meq) and DIPEA (5 meq) in DMF. Couplings
were monitored by the quantitative ninhydrin test. The peptide was
deprotected and cleaved from the solid support with liquid HF, p-cresol
at 5 °C for 1–2 h. Crude peptide was purified by reverse-phase HPLC
and lyophilized overnight (30%). Stock solutions of peptides were pre-
pared in water and kept at 80 °C until use. Peptide substrates were
Ac-RTSKKR-pNA, Ac-EVKKQR-pNA, Ac-FAAGRK-pNA, Ac-TTSTRR-
pNA, and Ac-EVKKQRAGVL-OH corresponding to pNA analogues of
the 2A/2B, 2B/3, 3/4A, and 4B/5 cleavage sites and a 10-amino acid
segment derived from the 2B/3 site, respectively. Ac-RTSKKR-pNA,
retention time (Rt)  13.5 min, ESMS [MH]
  907.6, [M2H]2 
454.3; Ac-EVKKQR-pNA, Rt  15.3 min, ESMS [MH]
  949.7,
[M2H]2  475.3; Ac-FAAGRK-pNA, Rt  16.7 min, ESMS [MH]

 781.5, [M2H]2  391.3; Ac-TTSTRR-pNA, Rt  17.7 min, ESMS
[MH]  883.6, [M2H]2  442.3; and Ac-EVKKQRAGVL-OH, Rt
15.5 min, ESMS [MH]  1169.4, [M2H]2  585.5.
Protease Assays
A spectrophotometric assay was conducted, using peptide substrates
appended to a pNA chromophore, in 96-well plates with each well
containing a final volume of 200 l, an enzyme concentration of 0.5 or
1 M, and an incubation temperature of 37 °C. Each reaction was
monitored continuously by following the increase in A405 on a Spectra-
Max 250 reader. Initial velocities and substrate concentrations were
fitted by nonlinear regression to the Michaelis-Menten equation. pH
dependence experiments were carried out with the following buffers:
MES (pH 5.5–7.0), MOPS (pH 6.5–8.0), Tris (pH 7.5–9.0), ethanolamine
(pH 8.5–10.0), and CAPS (pH 10.0–11.5) together with an enzyme
concentration of 1 M, para-nitroanilide substrates at 500 M, and a
constant ionic strength (50 mM). For overlapping pH regions, the activ-
ity was shown to be unaffected by buffer composition. Buffers included
NaCl, glycerol, and detergents varied to optimize assay conditions (see
“Results”). Subsequent assays with pNA substrates were performed
under optimal conditions that involved 50 mM Tris, pH 9.0, 10 mM NaCl,
20% glycerol, 1 mM CHAPS for a final volume of 200 l in 96-well plate
format and 30 l for HPLC analysis. Cleavage of the 10-residue peptide
substrate was determined by analytical HPLC using a Waters system
equipped with a 717 plus autosampler, 660 controller, and a 996 pho-
todiode array detector. The enzyme concentration was 1 M, the incu-
bation temperature was 37 °C, the incubation time was 2 h (10%
substrate conversion), and the reaction was quenched by addition of 70
l of 0.1% TFA. Samples of 22.5–90 l were injected on a Vydac
reversed-phase column, and fragments were separated using a 0–100%
solvent B gradient at 5%/min. Peak detection was facilitated by moni-
toring A214 and quantified by integration of chromatograms with re-
spect to the appropriate standard peptide. Initial velocities (v) were
determined, and kinetic parameters were calculated from weighted
nonlinear regression of initial velocities as a function of eight substrate
concentrations [S] using GraphPad Prism® software. kcat/Km values
were calculated assuming Michaelis-Menten kinetics, v  Vmax[S]/([S]
 Km). Quadruplicate measurements were taken for each data point.
The data are reported as the means  S.E.
Inhibitor Assay
General protease inhibitors were used to confirm the presence of a
serine protease. Inhibitors were assayed in a 96-well plate format using
50 mM Tris, pH 9.0, 10 mM NaCl, 20% glycerol, 1 mM CHAPS in a final
volume of 200 l. Typically CF40.NS3pro (0.5 M) was preincubated
with various concentrations of test compounds at 37 °C for 10 min. The
reaction was initiated by the addition of substrate Ac-TTSTRR-pNA at
500 M. On the other hand the peptidic inhibitors were assayed using
CF40.gly.NS3pro (0.5 M) in a 96-well plate format using 50 mM
HEPES, pH 7.5, 50 mM NaCl, 20% glycerol, 1 mM CHAPS in a final
volume of 200 l. Typically these test compounds were incubated with
the enzyme conjugate at 37 °C for 50 min, and then substrate cleavage
was initiated by the addition of the chromogenic substrate Ac-TTSTRR-
pNA at 500 M. Reaction progress was monitored continuously by
following the increase in A405 on a SpectraMax 250 plate reader. IC50
values were determined for inhibitors from substrate titration experi-
ments performed in the presence of increasing inhibitor concentration
using Dixon plots (1/v versus [I]). Ki values were calculated from IC50
values according to the equation, Ki  IC50/(1  S/Km). Triplicate
measurements were taken for each data point. The data are reported as
the means  S.E.
Peptide Inhibitors
-Keto Amide Inhibitors (1–3)—Inhibitors 1 (Ac-FAAGRR-{CO-
CONH}-SL-CONH2), 2 (Ac-TTSTRR-{COCONH}-SL-CONH2), and 3
(Ac-TTSTRR-{COCONH}-GTGN-CONH2) were synthesized on 4-meth-
ylbenzhydrylamine resin (substitution value  0.59mmol/g). The pep-
tides were assembled by stepwise solid phase synthesis using the Boc
protocol. Protecting groups for individual amino acids were: Arg (Tos),
Ser (Bzl), and Thr (Bzl). Removal of the Boc protecting group was
effected by shaking the resin twice with 1-min treatments with TFA. All
amino acids (4 meq) were activated by HBTU (4 meq) and DIPEA (5
meq) in DMF with the exception of Boc-Arg(Tos)--hydroxy acid (2
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meq), which was activated with PyBOP (2 meq) and DIPEA (3 meq) in
DMF. Couplings were monitored by the quantitative ninhydrin test. All
peptides were acetylated using activated acetic acid with HBTU/DIPEA
in DMF after the final Boc deprotection. The -hydroxyl moiety was
oxidized on resin with Dess Martin Periodinane (2 meq) in dry Me2SO for
2 h at room temperature to give the desired -keto amides. The inhibitors
were deprotected and cleaved from the solid support with liquid HF,
p-cresol at5 °C for 1–2 h, during which time partial racemization occurs
at P1 arginine, producing a mixture of two diastereoisomers. These -keto
amides are also unstable in basic solutions. Crude peptides were purified
by reversed-phase HPLC and characterized by analytical HPLC and
electrospray mass spectrometry. Analytical HPLC (gradient, 0–100% sol-
vent B over 30 min): 1, Rt 16.1 min, ESMS [MH]
  946.8, [M2H]2
 473.9; 2, Rt 14.1 min, ESMS [MH]
  990.8, [M2H]2  495.9; 3,
Rt  12.2 min, ESMS [MH]
  1119.6, [M2H]2  560.3.
Synthesis of Boc-Arg(Tos)--hydroxy Acid—Boc-Arg(Tos)-OH was ac-
tivated with BOP/DIPEA in DCM and reacted with N-methyl-O-meth-
ylhydroxylamine hydrochloride to give the Weinreb amide in a yield of
81%. The amide was reduced with LiAlH4 in THF at 0 °C, giving the
aldehyde in good yield (99%). The aldehyde was treated with KCN to
generate the cyanohydrin, which was partially purified by passage
through a short column of silica and treated directly with concentrated
HCl at room temperature for 3 days. Subsequent neutralization to pH
6 gave the unprotected -hydroxy acid as colorless crystals (53%). The
-hydroxy acid could be protected at the amino terminus as the Boc or
Fmoc derivative by using either Boc-carbonate or Fmoc-OSu in basic
solution under standard conditions (66%).
Boc-Arg(Tos)-NMeOMe—Boc-Arg(Tos)-COOH (10.0 g, 23.4 mmol)
and N-methyl-O-methyl-hydroxylamine hydrochloride (2.27 g, 23.4
mmol) were dissolved in DCM (50 ml). BOP (10.3 g, 23.4 mmol) and
DIPEA (12.2 ml, 70.2 mmol) were added to the stirred mixture and
allowed to react for 45 min at room temperature. To this solution was
added 10% KHSO4 solution (20 ml), and the mixture was extracted with
DCM (3  50 ml). The organic layers were combined and washed with
10% KHSO4 (2  50 ml), saturated NaHCO3 (3  50 ml), water (3  50
ml), and brine (3 50 ml). The organic layer was dried with MgSO4 and
concentrated in vacuo to yield product as an oil, which was triturated
with a small volume of ethyl acetate (20 ml) to give a white powder. The
powder was filtered and dried (9.0 g, 81%). ESMS [MH]  472.3; 1H
NMR (CDCl3)  7.77 (d, 2H, Ar-H), 7.23 (d, 2H, Ar-H), 6.55 (br.s, 2H,
NH), 5.56 (d, 1H, Boc-NH), 4.62 (m, 1H, CH), 3.72 (s, 3H, O-Me), 3.36
(m, 1H, CH), 3.20 (s, 3H, N-Me), 3.18 (m, 1H, CH), 2.40 (s, 3H,
Ar-CH3), 1.64 (m, 4H, CH2 and CH2), 1.42 (s, 9H, Boc).
Boc-Arg(Tos)-CHO—Boc-Arg(Tos)-NMeOMe (15.0 g, 31.8 mmol) was
dissolved in anhydrous THF (200 ml) and stirred under argon at 0 °C.
LiAlH4 (2.0 g, 31.8 mmol) was added in small portions and stirred for
1 h at 0 °C. The reaction mixture was poured into 10% KHSO4 solution
(100 ml) and extracted with EtOAc (3  100 ml). The organic layers
were combined and washed with 10% KHSO4 (3  100 ml), water (3 
100 ml), and brine (3 100 ml). The EtOAc layer was dried with MgSO4
and concentrated in vacuo to yield product as white powder (13.0 g,
99%). The aldehyde was not purified further but used directly in sub-
sequent transformations. ESMS [MH]  413.2; 1H NMR (CDCl3) 
7.74 (d, 2H, Ar-H), 7.25 (d, 2H, Ar-H), 6.79 (br.s, 1H, NH), 5.66 (s, 1H,
aminol-CH), 5.23 (br.s, 1H, NH), 5.05 (d, 1H, Boc-NH), 3.5–3.75 (br.m,
2H, CH, and CH), 3.14 (m, 1H, CH) 2.40 (s, 3H, Ar-CH3), 1.45–1.80
(m, 4H, CH2, and CH2), 1.41 (s, 9H, Boc).
H-Arg(Tos)--hydroxy Acid—Boc-Arg(Tos)-CHO (13.0 g, 31.4 mmol)
was dissolved in EtOAc (65 ml). KCN (3.54 g) was dissolved in 1:1
mixture of methanol and water (70 ml) and added to the aldehyde. The
homogenous reaction mixture was stirred overnight. The mixture was
diluted with water (50 ml), and the organic layer was washed with
water (3  100 ml). The EtOAc layer was dried with MgSO4 and
concentrated in vacuo to an orange oil that was passed through a short
column of silica (30% EtOAc/hexane eluant) to remove base-line mate-
rial. The resultant oil hydrolyzed with concentrated HCl (60 ml) at room
temperature for 3 days. The solution was reduced to dryness, redis-
solved in water (60 ml), and neutralized to pH 6 with 2 M NaOH
solution. The desired product existed as two diastereoisomers and pre-
cipitated as colorless crystals (6.0 g, 53%). ESMS [MH]  359.2.
Boc-Arg(Tos)--hydroxy Acid—H-Arg(Tos)--hydroxy acid (0.81 g,
2.3 mmol) was dissolved in 1:1 THF/water (10 ml). 2 M NaOH solution
(2.3 ml, 4.5 mmol) was added, and the reaction was cooled to 0 °C.
Boc-carbonate (0.74 g, 3.4 mmol) was added and stirred for 1 h at 0 °C.
The reaction was allowed to warm to room temperature and stirred
overnight. THF was removed in vacuo, and the residue was diluted with
water (10 ml). The basic aqueous layer was extracted with EtOAc (3 
30 ml). The aqueous layer was subsequently acidified with 10% KHSO4
(20 ml) and extracted with EtOAc (3  30 ml). The organic layer was
washed with water (3  50 ml), dried with MgSO4, and concentrated in
vacuo to yield product as a white solid (0.68 g, 66%). ESMS [MH] 
459.3. 1H NMR (CDCl3) (The two diastereomeric products had coinci-
dent NMR spectra; only the two Boc signals at  1.40, 1.43 were
resolved)  7.5 (m, 4H, Ar-H), 7.22 (m, 4H, Ar-H), 6.35 (m, 4H, NH 
NH), 5.20 (m, 2H, BocNH), 4.67 (m, 2H, CH), 4.00 (m, 2H, CH), 3.18
(m, 4H, CH2), 2.38 (s, 6H, CH3), 2.27 (m, 6H, OH COOHNH), 1.54
(m, 8H, CH2  CH2), 1.43 (s, 9H, Boc), 1.40 (s, 9H, Boc).
Arginal Inhibitor (4)—The method developed for the synthesis of
Ac-FAAGRR-CHO (4) is a modification of the Corvas procedure (25–28)
and used arginine protected as the cyclol synthon. Our modifications to
the literature procedure entailed the use of phosphonium coupling
reagents instead of mixed anhydride methods and of more strongly
acidic solvent for the hydrogenolysis of the nitro guanidine protecting
group. Instead of assembling short arginals as reported (25–28), we
utilized solid phase peptide synthesis to assemble the pentapeptide
Ac-FAAGR-COOH, which was then coupled in solution to the cyclol.
Ac-FAAGR-OH—The pentapeptide acid was assembled by standard
manual Fmoc solid phase peptide synthesis using Novabiochem Fmoc-
Arg(pmc)-Wang resin (substitution value  0.54 mmol/g) as described
above. HRMS calculated for C25H38N8O7 [MH]
 563.2936, found
563.2935. 1H NMR (Me2SO-d6)  8.18 (d, 1H, AlaNH), 8.15 (t, 1H,
GlyNH), 8.12 (d, 1H, PheNH), 8.03 (d, 1H, ArgNH), 8.02 (d, 1H, AlaNH),
7.59 (bs, 1H, Arg-NH), 7.4–6.8 (bs, 4H, NH2  NH2), 7.24 (m, 4H,
Ar-H), 7.17 (m, 1H, Ar-H), 4.50 (m, 1H, PheCH), 4.28 (m, 1H, AlaCH),
4.25 (m, 1H, AlaCH), 4.22 (m, 1H, ArgCH), 3.74 (m, 2H, GlyCH),
3.32 (bs, 1H, COOH), 3.10 (m, 2H, ArgCH2), 3.00 (m, 1H, PheCH),
2.73 (m, 1H, PheCH), 1.78–1.49 (m, 4H, ArgCH2  ArgCH2), 1.73
(s, 6H, CH3).
N--Boc-N--nitroarginine Lactam—To a stirred suspension of N--
Boc-N--nitroarginine (6.38 g, 20 mmol) and BOP (9.72 g, 20 mmol) in
THF (120 ml) was added DIPEA (10.4 ml, 60 mmol), and the solution
was stirred at room temperature overnight. The solvent was removed
under vacuum, and the residue was partitioned between EtOAc (400
ml) and hydrochloric acid (1 M, 200 ml). The organic extract was washed
with hydrochloric acid (1 M, 2 200 ml), dried with MgSO4, filtered, and
evaporated to yield the crude product as a yellow foam. Column chro-
matography (10% EtOAc/DCM) yielded pure product (3.01 g, 50%) as a
white foam. ESMS [MH]  302.1. 1H NMR (CDCl3)  10.40 (bs, 1H,
NH), 9.53 (bs, 1H, NH), 5.15 (m, 1H, BocNH), 4.65 (m, 1H, CH), 4.46
(m, 1H, CH), 3.56 (m, 1H, CH), 2.48 (m, 1H, CH), 1.95 (m, 2H,
CH2), 1.63 (m, 1H, CH), 1.48 (m, 9H, Boc).
N--Boc-N--nitroargininal Ethyl Cyclol—To a stirred solution of
LiAlH4 in THF (1.0 M, 10 ml, 10 mmol) cooled in an ice bath was added
dropwise EtOAc (1.13 ml, 10 mmol) in THF (5 ml). The solution was
stirred for 30 min at 0 °C and treated with a solution of N--Boc-N--
nitro-L-arginine lactam (3.01 g, 10 mmol) in THF (15 ml). The mixture
was stirred for 30 min at 0 °C and treated with a mixture of hydrochlo-
ric acid (1 M, 3 ml) and THF (3 ml) dropwise, followed by hydrochloric
acid (1 M, 60 ml) at room temperature. The solution was extracted with
EtOAc (3  60 ml), washed with saturated NaHCO3 (15 ml), brine (20
ml), dried with MgSO4, filtered, and evaporated to yield the crude
aldehyde as a white foam. ESMS [MH]  304.2. The crude aldehyde
was dissolved in ethanol (15 ml), and concentrated HCl (50 l) was
added. The mixture was stirred at room temperature for 7 h, and the
solvent was removed under vacuum. The crude product was purified by
column chromatography (0–10% EtOAc/DCM to yield 1.72 g (52%) of
the title compound as a white foam. ESMS [MH]  332.2.
N--Nitroargininal Ethyl Cyclol.TFA—N--Boc-N--Nitroargininal
ethyl cyclol (1.72 g, 5.2 mmol) was treated with 50% TFA/DCM (5.6 ml)
for 10 min. The solution was added dropwise to diethyl ether (50 ml)
with swirling. The product was collected at the pump, washed briefly
with diethyl ether (3  100 ml), and dried under vacuum to yield pure
product (1.13 g, 63%). ESMS [MH]  232.1. 1H NMR (Me2SO-d6) 
8.74 (bs, 1H, NH), 8.05 (bs, 1H, NH), 5.93 (m, 1H, CH), 3.74 (m, 1H,
CH), 3.51 (m, 1H, 1/2 of CH2), 3.45 (m, 1H, 1/2 of CH2), 3.32 (m,
3H,
NH3), 3.27, (m, 1H, CH), 3.03 (t, 1H, CH), 1.76 (m, 3H, CH2  CH),
1.55 (m, 1H, CH), 1.19 (t, 3H, CH3).
Ac-FAAGR--nitroarginal Ethyl Cyclol—To a stirred solution of Ac-
FAAGR-OH (30.4 mg, 0.054 mmol), BOP (22 mg, 0.05 mmol), and cyclol
TFA salt (31 mg, 0.09 mmol) in DMF (1.5 ml) was added DIPEA (39 l,
5 meq). The mixture was stirred at room temperature for 3 h, and the
solvent was removed under reduced pressure. The residue was purified
by preparative HPLC (gradient: 0–100% B over 50 min, Rt  12.5 min)
to yield the product as a white powder. ESMS [MH]  776.6.
Ac-FAAGR-arginal Ethyl Cyclol—To a solution of the above ni-
troarginal ethyl cyclol in a mixture of water (1 ml), ethanol (1 ml), and
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acetic acid (glacial, 15 ml) was added palladium-on-carbon catalyst
(10%, 30 mg), and the mixture was hydrogenated in a Parr apparatus at
45 p.s.i. H2 for 48 h. The mixture was filtered through Celite and
washed with water, and the solvent was removed under reduced pres-
sure to yield the product as a colorless residue. ESMS [MH]  731.4.
Ac-FAAGR-arginal (4)—A solution of the above arginal ethyl cyclol in
water (5 ml) was cooled in an ice bath and treated with hydrochloric
acid (10 M, 45 l). The reaction was monitored by mass spectrometry
and when complete (2.5 h) was quenched by the addition of sodium
acetate solution (2.5 M, 1 ml). The solution was filtered, and the product
was purified by preparative HPLC (gradient: 0–100% solvent B over 50
min, Rt  9.1 min) to yield the product as a white powder. The
1H NMR
spectrum of the aldehyde in water showed three sets of resonances
(4:1:1 ratio) attributable to the two diastereomeric closed aminol forms
and one open chain hydrate form of the aldehyde. HRMS calculated for
C31H50N12O8 [MH]
  703.3998, found  703.3989.
RESULTS
In Vitro Expression of Catalytically Active NS3pro—The first
aim of this study was the expression and purification of a
catalytically active recombinant dengue virus NS3 protease,
initially for use in in vitro based assays. To confirm that the
sequences we derived by reverse transcription-PCR from a
dengue virus-infected cell RNA encoded an active protease, we
first expressed these recombinant proteins in a rabbit reticu-
locyte-coupled transcription/translation system (Fig. 2A).
pTM.NS2B.NS3pro encodes the NS2B gene, which is an essen-
tial co-factor for proteolytic activity, fused to the first 184
amino acids of the NS3 protease (NS3pro). Similar constructs
have previously been shown to exhibit cis cleavage at the
NS2B-NS3 junction when expressed either by recombinant
vaccinia viruses (3) or in in vitro reticulocyte lysate translation
systems employing microsomal membranes (17). As shown in
Fig. 2A, expression of pTM.NS2B.NS3pro in a reticulocyte ly-
sate supplemented with microsomal membranes (lane 1)
clearly demonstrates processing of the 34-kDa NS2B.NS3pro
precursor product into the expected 20-kDa NS3pro. In the
absence of microsomal membranes, processing is less efficient,
indicating the likely misfolding of the highly hydrophobic
NS2B (Fig. 2A, lane 2). Given the hydrophobic nature of NS2B,
with three predicted membrane-spanning domains (29), ex-
pression in association with NS3pro in E. coli would likely
generate an insoluble product. However, Clum et al. (17) have
shown that expression of the central conserved 40-amino acid
hydrophilic domain of NS2B fused to NS3pro was sufficient for
efficient co-factor activity. We generated a similar construct,
pTM.CF40.NS3pro, and showed highly efficient processing of
the expressed product in vitro in the absence of microsomal
membranes (Fig. 2A, lane 4). Indeed, processing appeared com-
plete with no precursor product apparent in the SDS-PAGE
profile. It is possible that cleavage was mediated not by the
cis-activity of NS3pro but via trans-cleavage by a contaminat-
ing protease. This possibility was addressed by mutation of one
of the amino acids comprising the catalytic triad of NS3pro,
Ser135 3 Ala to generate pTM.CF40.NS3pro. Expression of
this construct yielded the expected 32-kDa CF40.NS3pro pre-
cursor with no detectable cleavage (Fig. 2A, lane 6), demon-
strating that the processing of pTM.CF40.NS3pro was due to
the cis-activity of a catalytically active NS3pro. The additional
species at 28 kDa for both pTM.CF40.NS3pro and
pTM.CF40.NS3pro (Fig. 2A, lanes 4 and 6) was likely the
product of internal initiation of translation at a downstream
start codon.
Expression and Purification of NS3pro and CF40.NS3pro—
To facilitate purification of E. coli expressed recombinant pro-
teins, we used the pQE9 vector, which incorporates an amino-
terminal hexahistidine tag allowing convenient purification by
Ni2 affinity chromatography. After the commencement of this
project, Yusof et al. (18) reported a similar expression strategy
and noted that although both NS3pro and an equivalent ver-
sion of CF40.NS3pro were produced at high levels, the ex-
pressed proteins were found associated with insoluble inclusion
bodies. Their solution was to purify urea-denatured recombi-
nant protein from the insoluble pellet fraction of bacterial cell
lysates and then refold the expressed products by successive
dialysis. We investigated this approach but found that the
refolding dialysis step consistently led to unacceptable levels of
precipitation and poor recovery. Instead, we focused on opti-
mizing expression conditions that favored the generation of
soluble recombinant protein. Investigation of a range of param-
eters (data not shown) indicated that expression at 30 °C
yielded low but acceptable levels of soluble protein (Fig. 2B,
lanes 4 and 9) when purified by Ni2 column affinity chroma-
tography (Fig. 2B, lanes 6 and 11). This was particularly ap-
parent for the CF40.NS3pro recombinant, which is suggestive
of a chaperone-like function for CF40/NS2B in mediating the
correct folding of NS3pro. Furthermore, although the majority
of expressed recombinant in the insoluble pellet was uncleaved
precursor (Fig. 2B, arrowhead in lane 10), the correct folding of
FIG. 2. In vitro translation of NS2B/NS3 constructs and expres-
sion in E. coli. A, pTM constructs encoding NS2B.NS3pro (lanes 1 and
2), NS3pro (lanes 3 and 5), CF40.NS3pro (lane 4), and CF40.NS3pro
(lane 6) were expressed in vitro in a coupled transcription/translation
reaction, TnT. Incubations were carried out with or without canine
pancreatic microsomal membranes as indicated, and products of cis-
mediated cleavage were examined by SDS-PAGE and autoradiography.
B, pQE9 recombinant constructs NS3pro and CF40.NS3pro were ex-
pressed in E. coli, and cell lysates were examined by SDS-PAGE and
Coomassie Blue staining. The samples analyzed included protein mo-
lecular mass markers (M, lane 1), uninduced cell lysates (U, lanes 2 and
7), 1 mM induced cell lysates (I, lanes 3 and 8), the soluble fraction
following lysis using a French press (S, lanes 4 and 9), and the insoluble
pellet fraction (P, lanes 5 and 10). His-tagged recombinant products
were purified by Ni2 affinity chromatography from the soluble frac-
tions of cell lysates (lanes 6 and 11).
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the soluble form of the CF40.NS3pro complex was evidenced by
its complete processing to the 20-kDa NS3pro and the 8-kDa
co-factor domain (Fig. 2B, lane 11). Two additional intermedi-
ate species were also consistently identified in varying levels
(indicated by arrowheads in Fig. 2B, lane 11). These were
amino-terminally sequenced and shown to be truncated amino-
terminal CF40.NS3pro products of auto-catalytic cleavage by
CF40.NS3pro.
Characterization of Enzymatic Activity—To investigate
whether CF40.NS3pro had proteolytic activity against small pep-
tide substrates, we initially used buffer conditions similar to
those reported for the hepatitis C virus NS3 protease (50 mM
HEPES, pH 7.5, 70 mM NaCl, 20% glycerol, 0.1% Triton X-100).
Reversed-phase HPLC was used to examine cleavage of the 10-
residue peptide Ac-EVKKQRAGVL-COOH derived from the
NS2B/NS3 site. Analytical HPLC (Fig. 3) showed the expected
cleavage products Ac-EVKKQR-COOH and NH2-AGVL-COOH,
their identities being established by molecular mass determina-
tion through mass spectrometry and HPLC. The rate of cleavage
of the decapeptide was slow. To optimize the enzyme processing
conditions and to facilitate continuous monitoring of this reac-
tion, we constructed the analogous chromogenic para-nitroani-
lide substrate Ac-EVKKQR-pNA corresponding to the P6-P1 seg-
ment amino-terminal to the NS2B-NS3 cleavage site but with a
more reactive, hydrolytically cleavable, para-nitroanilide at the
P1 position. By monitoring the absorbance increase at 405 nm as
a function of time, we were able to quantitatively compare the
rates of processing of this substrate with Ac-RTSKKR-pNA, Ac-
FAAGRK-pNA, and Ac-TTSTRR-pNA, corresponding to the
NS2A/NS2B, NS3/NS4A, and NS4B/NS5 cleavage sites, respec-
tively. We chose the most rapidly cleaved substrate (NS4B/5) to
further examine the effects of diluents on substrate processing.
Effect of pH, Salt, Glycerol, and Detergents on Enzyme Activ-
ity—Using 1 M purified CF40.NS3pro, we found that the sub-
strate Ac-TTSTRR-pNA was cleaved most rapidly and most
efficiently at a concentration of 500 M, which was therefore
used to optimize assay conditions. The pH dependence for
enzyme processing was determined at a constant ionic strength
(I  50 mM) using various buffers with overlapping pH ranges
between pH 5.5 and 11.5. These were MES (pH 5.5–7.0), MOPS
(pH 6.5–8.0), Tris (pH 7.5–9.0), ethanolamine (pH 8.5–10.0),
and CAPS (pH 10.0–11.5). The optimum pH for proteolytic
processing was found to be 9.2, but above pH 9.5 the pNA
substrate itself begins to undergo base-catalyzed hydrolysis in
the absence of enzyme (Fig. 4A). At pH 9.0, base-catalyzed
cleavage of pNA was negligible, whereas the enzyme was about
five times more active in processing substrate than at a pH of
7.5. We therefore chose a 50 mM Tris buffer at pH 9.0 for
investigating substrate cleavage.
Fig. 4B shows that increasing ionic strength has a significant
effect on substrate processing, with the protease being suscep-
tible to inhibition by salt at higher ionic strengths. This has
also been observed for the hepatitis C NS3 protease. The min-
imum ionic strength (I) for 50 mM Tris at pH 9.0 was 10 mM;
therefore this ionic strength was used in further work. Because
NS3pro is thought to be membrane-associated, the effects of
glycerol and detergents were also investigated to test their
effect on enzyme efficiency. A titration experiment using glyc-
erol indicated that optimal activity was obtained in the pres-
ence of 20% glycerol (Fig. 4C), with activity being improved
about 1.3-fold over no glycerol. We also determined the effect of
different zwitterionic and nonionic detergents on the enzymatic
activity, and although Triton X-100, BRIJ-35, and CHAPS at
0.05–0.5% all increased activity, there were no significant dif-
ferences between detergents (data not shown). For ease of
handing, 1 mM CHAPS was subsequently used in cleavage
experiments. Hence, our optimal buffer composition for sub-
strate cleavage was 50 mM Tris, pH 9.0, 10 mM NaCl, 20%
glycerol, and 1 mM CHAPS. The optimization of this simple in
vitro assay for dengue virus NS3 protease activity in a 96-well
format should prove invaluable for supporting not only struc-
ture-based drug design but also for high throughput screening
of libraries of compounds for candidate lead inhibitors.
By analogy with the HCV NS3 protease where co-factor
activity can be supplied in trans with a small 14-amino acid
peptide derived from NS4A (30, 31), we had earlier proposed
that an equivalent central hydrophobic 14-amino acid domain
(70GSSPILSITISEDG83) within the previously identified 40-
amino acid region of the flavivirus NS2B co-factor may be
sufficient for activity (29). The availability of a sensitive in vitro
assay now allowed us to test this hypothesis. A 13-residue
peptide based on the sequence (NH2-
69SGSSPILSITISE81-
COOH) was added as a putative co-factor to NS3pro, and the
mixture was assayed. This peptide did not activate the protease,
unlike similar short peptides, which were co-factors for HCV
protease (data not shown). These data are supported by a recent
report for the yellow fever virus NS3 protease that demonstrates
that amino acids within the amino-terminal region of the 40-
amino acid co-factor domain may be involved in additional
charged interactions with NS3pro that are essential for activity
(32). A requirement for these residues would further distinguish
the flavivirus NS3 serine protease from its HCV counterpart.
Comparison of Peptide Substrates—The catalytic efficiency
and specificity of the CF40.NS3pro protease was examined by
FIG. 3. Reversed-phase HPLC anal-
ysis of the cleavage of Ac-EVKKQRA-
GVL-COOH by CF40.NS3pro. A, HPLC
profile of Ac-EVKKQRAGVL-COOH sub-
strate alone. The retention time on the
column is given in minutes, and peak
detection was monitored at A214 nm. B,
HPLC trace of the products of cleavage of
the Ac-EVKKQRAGVL-COOH substrate
after overnight incubation at 37 °C in the
presence of 1 M CF40.NS3pro.
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measuring kinetic parameters for processing of the pNA sub-
strate analogues of four hexapeptides corresponding to the
P6-P1 residues amino-terminal to four cleavage sites (2A/B,
2B/3, 3/4A, 4B/5) within the polypeptide precursor. The rate of
substrate hydrolysis and the Michaelis-Menten equilibrium
constants are markedly sequence-dependent (Fig. 4D), with the
sequences corresponding to the NS4B/NS5 and NS2B/3 cleav-
age sites being most rapidly cleaved. The rank order of kcat for
these pNA substrates is 4B/5	 2B/3		 2A/2B 3/4A (Table I).
These residues have either Arg-Arg or Gln-Arg at the P2-P1
positions. On the other hand Km varies in the order 2B/3 		
4B/5 		 2A/2B  3/4A leading to a rank order of substrate
efficiency or fitness as substrates (kcat/Km): 4B/5 	 3/4A 	
2A/2B 	 2B/3 (Table I). Interestingly the decapeptide Ac-
EVKKQRAGVL-COOH, corresponding to the 2B/3 cleavage
site, is processed less efficiently than the corresponding
hexapeptide-pNA substrate Ac-EVKKQR-pNA (Table I).
Inhibition By Standard Serine Protease Inhibitors—The effect
of standard protease inhibitors on substrate processing by
CF40.NS3pro was also investigated. The percentage of cleavage
in the presence of added inhibitors was determined as residual
activity with respect to the control sample in the absence of
inhibitors (Fig. 5). Aprotinin was shown to inhibit the enzyme
(IC50  65 nM), whereas other standard serine protease inhibi-
tors such as 4-(2-aminoethyl) benzenesulfonyl fluoride.hydro-
chloride and N-Tosyl-L-phenylalanine chloromethyl ketone
showed only 20–30% inhibition at 500 M and 1 mM, respectively.
Other serine protease inhibitors for which no enzyme inhibition
was found included soybean trypsin inhibitor (50 M), 4-Amidi-
nophenylmethanesulfonyl fluoride.hydrochloride (0.5 mM), phen-
ylmethylsulfonyl fluoride (0.5 mM), leupeptin (0.5 mM), pepstatin
A (0.1 mM), benzamidine (1 mM), and N-Tosyl-L-lysine chloro-
methyl ketone.hydrochloride (0.5 mM). The effect of divalent cat-
ions (Ca2, Mg2, and Mn2) was also investigated with the
addition of 20 mM CaCl2, 50 mM MgCl2, or 50 mM MnCl2 having
no effect on dengue virus NS3 protease activity. The failure of 1
mM EDTA to inhibit the enzyme (data not shown), further con-
firmed that divalent cations are not critical for enzyme activity.
Expression, Purification, and Enzymatic Characterization
of CF40.gly.NS3pro—SDS-PAGE analysis of the purified
CF40.NS3pro fractions eluted from the Ni2 affinity column
revealed that the products of cis cleavage (His-CF40 and
NS3pro) were not necessarily in equimolar proportions (Fig.
2B, lane 11) and therefore may not display optimal enzyme
kinetics. As a consequence of cleavage within E. coli, the re-
combinant CF40.NS3pro complex was purified via binding of
the His tag fused to the amino terminus of CF40. Varying levels
of imidazole were shown, however, to preferentially elute the
tightly but noncovalently bound NS3pro from the complex
(data not shown). Mass spectrometry confirmed that we had
not purified the CF40 and NS3pro components in equimolar
quantities (data not shown). Our earlier modeling of the den-
TABLE I
Kinetic parameters for the hydrolysis of synthetic peptide substrates
by dengue CF40.NS3pro at 37 °C
Substrate Km kcat kcat/Km
M s1 M1 s1
Ac-RTSKKR-pNA (2A/2B) 98  8 0.019  0.001 191  13
Ac-EVKKQR-pNA (2B/3) 1079  58 0.077  0.002 72  3
Ac-FAAGRK-pNA (3/4A) 78  5 0.017  0.001 219  9
Ac-TTSTRR-pNA (4B/5) 346  28 0.095  0.002 275  17
Ac-EVKKQRAGVL-OH 4239  294 0.169  0.007 40  2
FIG. 4. Characterization of the enzymatic properties of CF40.NS3pro. A, pH dependence of CF40.NS3pro. Processing of substrate
Ac-TTSTRR-pNA (500 M) by CF40.NS3pro (1 M) at constant ionic strength (I  50 mM (NaCl)) using different pH buffers (50 mM MES, MOPS,
Tris, ethanolamine, or CAPS) in the pH range of 5.5 to 11.5 () compared with hydrolysis of the substrate under the same conditions in the absence
of enzyme (f). B, effect of ionic strength; processing of substrate Ac-TTSTRR-pNA (500 M) by CF40.NS3pro (1 M) at pH 9.0 (50 mM Tris) in the
presence of a varying NaCl concentration. C, dependence on glycerol concentration; processing of substrate Ac-TTSTRR-pNA (500 M) by
CF40.NS3pro (1 M) at pH 9.0 (50 mM Tris) in the presence of a varying concentration of glycerol. D, Km determination of pNA substrates based
on cleavage sites NS2A/2B (f, 2A/2B), NS2B/3 (Œ, 2B/3), NS3/4A (, 3/4A), NS4B/5 (, 4B/5) and a 10-residue peptide substrate based on the
NS2B/3 cleavage site (, 2B/3*). Km was determined using CF40.NS3pro at 1.0 M in 50 mM Tris, pH 9.0, 10 mM NaCl, 20% glycerol, 1 mM CHAPS.
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gue virus NS3 protease complexed with its co-factor (29) indi-
cated that the carboxyl terminus of the co-factor was likely to
be in close proximity to the amino terminus of NS3pro, sug-
gesting the possibility of incorporating a short linker between
the two domains that would not disrupt the structural integrity
of the complex. So, to remedy the problems associated with
purifying a noncovalently bound complex, we engineered a new
construct that expressed a catalytically active NS3pro fused to
CF40 via a noncleavable, flexible nonapeptide (Gly4SerGly4)
linker, the fusion protein designated as CF40.gly.NS3pro (Fig.
1B). Expression of this construct resulted in substantially
higher levels of recombinant protein being found in the soluble
fraction of the bacterial cell lysate (Fig. 6A, lane 4) with yields
of purified CF40.gly.NS3pro (Fig. 6A, lane 6) approaching 50
mg/L of culture.
Using 1 M purified CF40.gly.NS3pro and 500 M Ac-
TTSTRR-pNA, the pH dependence for enzyme processing was
determined at a constant ionic strength (I  50 mM) using the
same buffers as described in the previous section with overlap-
ping pH ranges between pH 5.5 and 11.5. The optimum pH for
proteolytic processing was again found to be pH 9.2 (Fig. 6B).
By comparison the glycine-linked conjugate enzyme
CF40.gly.NS3pro was significantly more catalytically active
(about 4-fold) than the CF40.NS3 construct under the same
conditions (Fig. 6B). The enzyme kinetics of CF40.gly.NS3pro
were investigated using the same pNA substrates described
above and the same reaction conditions that had been opti-
mized for CF40.NS3pro. The results presented in Fig. 6C and
Table II indicate that although the binding affinities (Km) of
the substrates for CF40.gly.NS3pro were similar to those for
CF40.NS3pro, the catalytic rates (kcat) were significantly
higher, leading to higher overall proteolytic efficiencies (kcat/
Km) for the covalently linked (noncleavable) form. In summary,
the data in Fig. 6 (B and C) demonstrate that the glycine-linked
enzyme is the more active form. We attribute this to the ab-
sence of cleavage between co-factor and protease domains in
CF40.gly.NS3pro.
FIG. 6. Expression of CF40.gly.NS3pro in E. coli and charac-
terization of its enzymatic properties. A, the pQE9 recombinant
construct CF40.gly.NS3pro (see Fig. 1B) was expressed in E. coli, and
cell lysates were examined by SDS-PAGE and Coomassie Blue staining.
Samples analyzed include protein molecular mass markers (M, lane 1),
uninduced cell lysate (U, lane 2), 1 mM induced cell lysate (I, lane 3), the
soluble fraction following lysis using a French press (S, lane 4), and the
insoluble pellet fraction (P, lane 5). His-tagged recombinant products
were purified by Ni2 affinity chromatography from the soluble fraction
after cell lysis using a French press (lane 6). B, comparison of the pH
dependence of CF40.NS3pro (Œ) and CF40.gly.NS3pro (f). Processing
of substrate Ac-TTSTRR-pNA (500 M) by enzyme (1 M) at constant
ionic strength (I  50 mM (NaCl)) using different pH buffers (50 mM
MES, MOPS, Tris, ethanolamine, or CAPS) in the pH range of 5.5–11.5.
C, purified fractions eluted from the Ni2 affinity column were concen-
trated in a Centricon-10 column, and the enzymatic properties of a 1.0
M preparation were analyzed. Km determination was made with pNA
substrates based on cleavage sites NS2A/2B (f, 2A/2B), NS2B/3 (Œ,
2B/3), NS3/4A (, 3/4A), and NS4B/5 (, 4B/5). The reaction conditions
were as described for CF40.NS3pro, 50 mM Tris, pH 9.0, 10 mM NaCl,
20% glycerol, 1 mM CHAPS.
FIG. 5. Inhibitor profile of CF40.NS3pro. A range of inhibitors
were tested for their activity against CF40.NS3pro. The test compounds
were preincubated with 0.5 M CF40.NS3pro for 10 min at 37 °C fol-
lowed by the addition of the substrate Ac-TTSTRR-pNA at 500 M. The
reactions were performed in 50 mM Tris buffer, pH 9.0, 10 mM NaCl,
20% glycerol, 1 mM CHAPS in a final volume of 200 l in a 96-well plate
format. Bar 1, no inhibitor control; bar 2, soybean trypsin inhibitor (50
M); bar 3, 4-Amidinophenylmethanesulfonyl fluoride.hydrochloride
(0.1 mM); bar 4, 4-Amidinophenylmethanesulfonyl fluoride.hydrochlo-
ride (0.5 mM); bar 5, 4-(2-Aminoethyl) benzenesulfonyl fluoride.hydro-
chloride (0.1 mM); bar 6, 4-(2-Aminoethyl) benzenesulfonyl fluoride.hy-
drochloride (0.5 mM); bar 7, phenylmethylsulfonyl fluoride (0.5 mM); bar
8, leupeptin (0.1 mM); bar 9, leupeptin (0.5 mM); bar 10, aprotinin (3
M); bar 11, pepstatin A (0.1 mM); bar 12, benzamidine (1 mM); bar 13,
N-Tosyl-L-phenylalanine chloromethyl ketone (TPCK) (1 mM); bar 14,
N-Tosyl-L-lysine chloromethyl ketone.hydrochloride (TLCK) (0.5 mM);
bar 15, Me2SO (5%); bar 16, EDTA (1 mM).
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Synthetic Peptide Inhibitors—Peptidic -keto amide inhibi-
tors have been well characterized as reversible competitive
inhibitors for other serine proteases (33, 34), and most recently
keto amides were shown to be potent inhibitors of the closely
related HCV NS3 protease (35, 36). Fig. 7 shows several pep-
tides that were constructed as prospective inhibitors of
CF40.gly.NS3pro. Compound 1 was based on the P6-P2 resi-
dues of the 3/4A polypeptide cleavage sequence. Compound 2
contains the P6-P2 residues of the 4B/5 sequence, whereas
compound 3 has P6-P4 residues of the 4B/5 sequence. Com-
pound 1 was more potent (5-fold) than compounds 2 and 3
(Table III). All three compounds feature an -keto amide “tran-
sition state isostere” in place of the cleavable amide bond.
Lineweaver-Burk plots had the same ordinate intercept in the
presence or absence of inhibitor, indicating that the mechanism
was competitive (data not shown). Although the pH optimum
for the protease was pH 9, the assay for peptide inhibitors was
performed using CF40.gly.NS3 in 50 mM HEPES at more phys-
iologically relevant conditions (pH 7.5). The -keto amide in-
hibitors were found (37) to be unstable at pH 9 (data not
shown). When the cleavable amide bond and residues P1-P2
are removed from compound 1 and replaced with a carboxyl-
terminal aldehyde (e.g. 4), comparable inhibitory potency was
observed (Table III). The most potent inhibitors from this series
were 1 and 4, consistent with the 3/4A site pNA analogue
having the lowest Km.
DISCUSSION
Sequence alignment studies had previously indicated that
NS3pro would be structurally similar to trypsin-like serine
proteases, and this has been largely borne out by a recent
crystal structure of the free enzyme (38). However, unlike
trypsin, NS3pro has a marked preference for basic residues at
P2 and P1 in its peptide substrates in the vicinity of the
cleavage site. We considered that this unusual requirement
might provide an excellent basis for design of selective inhibi-
tors for this enzyme and, because of the essential nature of the
protease to viral replication, a possible basis for design of
antiviral agents. Toward this goal, the present work has exam-
ined enzymatic properties of the recombinant NS3 protease
(NS3pro) from the dengue virus, defined in a preliminary way
its enzymatic activity, identified and overcome difficulties with
autocatalytic cleavage of the co-factor from the protease, eval-
uated a series of short peptide substrates derivatized for spec-
trophotometric detection using a para-nitroaniline chro-
mophore, and taken the first steps toward inhibitor
development.
We found that, like other flavivirus proteases, NS3pro re-
quires a co-factor from the NS2B region for proteolytic activity.
Previous modeling and deletion studies had suggested that a
sequence of 40 amino acids from NS2B would likely contain the
requisite co-factor domain (16) and that a central core of 14
predominantly hydrophobic residues were thought to define
the essential co-factor (29). Although this is a similar situation
to the hepatitis C virus NS3 protease, unlike HCV we find that
(i) solutions of NS3pro and peptide substrate alone fail to lead
to proteolytic activity and (ii) addition of a synthetic 13-residue
peptide corresponding to the putative co-factor did not lead to
proteolysis (data not shown). However, when the dengue virus
NS3 protease was co-expressed with the 40-residue co-factor
sequence tethered to the amino terminus, substrate cleavage
was observed in cis and in trans. Homology modeling (29) had
previously suggested to us that this might be the case because
the co-factor appears to be required to thread through a narrow
channel of NS3pro for structural stability and therefore prob-
ably requires simultaneous folding of enzyme and co-factor to
lead to correctly bound co-factor for productive proteolysis.
FIG. 7. Dengue virus NS3pro peptide inhibitors. Inhibitors were
based on the dengue virus type 2 NS3/4A (structures 1 and 4) and
NS4B/5 (structures 2 and 3) cleavage sites and synthesized as described
under “Experimental Procedures.”
TABLE II
Kinetic parameters for the hydrolysis of synthetic peptide substrates
by dengue CF40.gly.NS3pro at 37 °C
Substrate Km kcat kcat/Km
M s1 M1 s1
Ac-RTSKKR-pNA (2A/2B) 96  7 0.087  0.001 903  56
Ac-EVKKQR-pNA (2B/3) 984  40 0.216  0.002 220  6
Ac-FAAGRK-pNA (3/4A) 100  9 0.043  0.001 425  30
Ac-TTSTRR-pNA (4B/5) 326  10 0.288  0.001 883  22
TABLE III
Inhibitors of dengue NS3 serine protease
Inhibitor Ki
M
1 Ac-FAAGRR-keto-SL-CONH2 47  3
2 Ac-TTSTRR-keto-SL-CONH2 220  55
3 Ac-TTSTRR-keto-GTGN-CONH2 368  47
4 Ac-FAAGRR-CHO 16  3
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Our initial work with NS3pro alone showed negligible proc-
essing of small pNA peptide substrates. When co-expressed
with co-factor (CF40.NS3pro), the enzyme demonstrated some
proteolytic activity (Table I) by cleaving small peptide sub-
strates, but mass spectrometry and reversed-phase HPLC sug-
gested that this enzyme-co-factor adduct was unstable in the
presence of protease, autocatalytically cleaving itself at the
CF40.NS3pro junction. This was confirmed when the kinetic
properties of the enzyme improved (Table II versus Table I) for
a more stable co-factor-protease construct (CF40-nonapeptide-
NS3pro) corresponding to the protease fused to the 40-residue
co-factor by a flexible nonapeptide linker (Gly4-Ser-Gly4). This
linker is not prone to enzymatic cleavage and thus prevents
enzymatic separation of co-factor from protease. These obser-
vations are in accordance with an equilibrium in the case of
CF40.NS3pro between intact and cleaved adduct, and the pa-
rameters obtained for this construct are similar to those re-
cently reported for a similar construct (18). Consequently, we
propose that a noncleavable linker between co-factor and pro-
tease, described for the first time herein, is needed for optimal
enzymatic activity.
By implication it would appear that NS2B functions as a
molecular chaperone in assisting the folding of NS3pro to an
active conformation that is presumably subtly different from
that reported in the recent crystal structure of the isolated
protease without co-factor (33). Other serine proteases (e.g.
-lytic protease, subtilisin) are known to require a pro-region
like NS2B for productive folding that leads to protease activity.
Once folding is completed, the pro-region is dispensable and
does not form a component of the active enzyme. In the case of
the hepatitis C virus NS3 protease, there was also a depend-
ence on Zn2 because of its structural role in stabilizing the
folding of the protease. Studies here with EDTA and divalent
cations confirmed our previous suggestion from homology mod-
eling (29) that metal ions are not important for protease activ-
ity. This is supported by the crystal structures of NS3pro (38,
39), which contained no metal ions.
We have also reported the first demonstration of cleavage
site preferences for NS3pro. The kinetic substrate profiles were
obtained using hexapeptide substrates modified as chromo-
genic pNA derivatives rather than the more tedious approach
using recombinant substrates. The observed cleavage efficiency
and selectivity profile (Tables I and II) for the four substrates
examined may provide useful clues for inhibitor development.
Interestingly, the longer decapeptide substrate was not cleaved
as efficiently as the pNA substrates, whereas for hepatitis C
virus NS3 protease the longer peptides are more effective sub-
strates (31). The crystal structure of free NS3pro suggests that
there may not be an essential requirement for amino acids in
the substrate beyond P2 on the carboxyl side of the scissile
bond for substrate binding (38).
Initial attempts here to investigate the inhibition of NS3pro
have revealed that this protease is not inhibited by standard
serine protease inhibitors (Fig. 5) except for aprotinin, which is
a potent inhibitor at submicromolar concentrations. However,
this inhibitor is a large protein and probably denies substrate
access to the protease active site by enveloping the enzyme.
Table III shows some preliminary indications that small mol-
ecule inhibitors, based upon the peptide substrates reported
herein, may be able to be developed as inhibitors of NS3pro.
Although the indicated compounds are only inhibitors at mi-
cromolar concentrations, we can expect to improve upon this
potency through structural optimization and with better car-
boxyl-terminal isosteres that permit more effective interaction
with catalytic residues of this serine protease. Because of the
critical and unusual requirement of dibasic residues for sub-
strates of this flavivirus NS3 protease, there would appear to
be good prospects for the design of protease inhibitors that
selectively inactivate NS3pro without inactivating essential
proteases for physiological function.
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